AU2021308209A1 - Isoquinoline compounds and their use in treating ahr imbalance - Google Patents
Isoquinoline compounds and their use in treating ahr imbalance Download PDFInfo
- Publication number
- AU2021308209A1 AU2021308209A1 AU2021308209A AU2021308209A AU2021308209A1 AU 2021308209 A1 AU2021308209 A1 AU 2021308209A1 AU 2021308209 A AU2021308209 A AU 2021308209A AU 2021308209 A AU2021308209 A AU 2021308209A AU 2021308209 A1 AU2021308209 A1 AU 2021308209A1
- Authority
- AU
- Australia
- Prior art keywords
- optionally substituted
- alkyl
- compound
- group
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063052574P | 2020-07-16 | 2020-07-16 | |
| US202063052561P | 2020-07-16 | 2020-07-16 | |
| US63/052,574 | 2020-07-16 | ||
| US63/052,561 | 2020-07-16 | ||
| PCT/US2021/034599 WO2022015423A1 (en) | 2020-07-16 | 2021-05-27 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021308209A1 true AU2021308209A1 (en) | 2023-02-09 |
| AU2021308209A8 AU2021308209A8 (en) | 2023-04-13 |
Family
ID=79293345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021308209A Pending AU2021308209A1 (en) | 2020-07-16 | 2021-05-27 | Isoquinoline compounds and their use in treating ahr imbalance |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US11267788B2 (enExample) |
| EP (2) | EP4786453A2 (enExample) |
| JP (1) | JP7867482B2 (enExample) |
| KR (1) | KR20230041021A (enExample) |
| CN (1) | CN116157387B (enExample) |
| AU (1) | AU2021308209A1 (enExample) |
| CA (1) | CA3185793A1 (enExample) |
| IL (1) | IL299756A (enExample) |
| MX (1) | MX2023000263A (enExample) |
| WO (1) | WO2022015423A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11267788B2 (en) | 2020-07-16 | 2022-03-08 | Dermavant Sciences GmbH | Isoquinoline compounds and their use in treating AhR imbalance |
| WO2024020170A1 (en) * | 2022-07-21 | 2024-01-25 | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. | Aryl hydrocarbon receptor agonist prodrugs and methods of use thereof |
| US20260069585A1 (en) * | 2022-08-30 | 2026-03-12 | Dermavant Sciences GmbH | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES |
| WO2024152993A1 (zh) * | 2023-01-17 | 2024-07-25 | 上海泽德曼医药科技有限公司 | 稠环类化合物、其制备方法及其在医药上的应用 |
| CN117447402A (zh) * | 2023-10-18 | 2024-01-26 | 德明药泰生物技术（深圳）有限公司 | 芳香烃受体调节剂类化合物及其制备方法和应用 |
| CN117229208B (zh) * | 2023-11-13 | 2024-02-23 | 上海泽德曼医药科技有限公司 | 稠环类化合物、其制备方法及其在医药上的应用 |
| WO2026083733A1 (ja) * | 2024-10-18 | 2026-04-23 | 株式会社ヤクルト本社 | 試験方法、ゲル状組成物、及び試験装置 |
| WO2026096218A1 (en) * | 2024-10-18 | 2026-05-07 | Dermavant Sciences GmbH | Pharmaceutical compositions for respiratory administration and methods of treating inflammatory diseases of the lungs |
| WO2026085237A1 (en) * | 2024-10-18 | 2026-04-23 | Dermavant Sciences GmbH | Process for preparing 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06504791A (ja) | 1991-04-10 | 1994-06-02 | オクタマー，インコーポレイティド | レトロウィルス複製の阻害のための方法 |
| US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| WO1999018077A1 (en) * | 1997-10-02 | 1999-04-15 | Eisai Co., Ltd. | Fused pyridine derivatives |
| DE60233414D1 (de) | 2001-07-09 | 2009-10-01 | Combinatorx Inc | Kombinationen für die behandlung entzündlicher erkrankungen |
| CN1596240A (zh) | 2001-12-19 | 2005-03-16 | 阿特罗吉尼克斯公司 | 查耳酮衍生物及其治疗疾病的用途 |
| WO2003053359A2 (en) | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
| EP1704856A4 (en) | 2003-12-26 | 2009-08-19 | Kyowa Hakko Kirin Co Ltd | PROTEIN INHIBITOR OF THE HSP90 FAMILY |
| WO2006058201A2 (en) | 2004-11-23 | 2006-06-01 | Reddy Us Therapeutics, Inc. | Heterocyclic and bicyclic compounds, compositions and methods |
| GB0704718D0 (en) | 2007-03-12 | 2007-04-18 | Prendergast Patrick T | Compounds and methods for preventing and treating mucositis |
| EP2014651A1 (en) | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Compounds and methods for modulating Rho GTPases |
| JP5439127B2 (ja) | 2009-11-13 | 2014-03-12 | 株式会社さいわいメディカル | 乾癬又はアトピー性皮膚炎治療剤 |
| US8933096B2 (en) | 2010-06-09 | 2015-01-13 | Rugers, The State University of New Jersey | Antimicrobial agents |
| GB201216017D0 (en) * | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| KR20150118106A (ko) | 2012-12-20 | 2015-10-21 | 알데이라 테라퓨틱스, 아이엔씨. | 페리-카르비놀 |
| GB201304041D0 (en) | 2013-03-06 | 2013-04-17 | Water Jel Europ Llp | Treatment and prophylaxis of radiation dermatitis |
| JP6899323B2 (ja) | 2014-10-14 | 2021-07-07 | ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー | 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用 |
| JP7138654B2 (ja) | 2017-03-29 | 2022-09-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 金属錯体 |
| WO2019018562A1 (en) | 2017-07-19 | 2019-01-24 | Ideaya Biosciences, Inc. | AMIDO COMPOUND AS MODULATORS OF AHR |
| CN111699192B (zh) | 2018-02-13 | 2024-03-08 | Udc爱尔兰有限公司 | 金属络合物 |
| TWI828664B (zh) | 2018-03-19 | 2024-01-11 | 愛爾蘭商Ｕｄｃ愛爾蘭責任有限公司 | 金屬錯合物 |
| US11267788B2 (en) | 2020-07-16 | 2022-03-08 | Dermavant Sciences GmbH | Isoquinoline compounds and their use in treating AhR imbalance |
| WO2023020512A1 (zh) * | 2021-08-16 | 2023-02-23 | 成都奥睿药业有限公司 | 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途 |
| CN116947799B (zh) * | 2023-03-08 | 2024-05-03 | 上海泽德曼医药科技有限公司 | 酚类化合物、其制备方法及其在医药上的应用 |
-
2021
- 2021-05-27 US US17/332,805 patent/US11267788B2/en active Active
- 2021-05-27 CN CN202180060054.5A patent/CN116157387B/zh active Active
- 2021-05-27 AU AU2021308209A patent/AU2021308209A1/en active Pending
- 2021-05-27 IL IL299756A patent/IL299756A/en unknown
- 2021-05-27 EP EP26186010.0A patent/EP4786453A2/en active Pending
- 2021-05-27 CA CA3185793A patent/CA3185793A1/en active Pending
- 2021-05-27 KR KR1020237005000A patent/KR20230041021A/ko not_active Ceased
- 2021-05-27 JP JP2023502881A patent/JP7867482B2/ja active Active
- 2021-05-27 MX MX2023000263A patent/MX2023000263A/es unknown
- 2021-05-27 WO PCT/US2021/034599 patent/WO2022015423A1/en not_active Ceased
- 2021-05-27 EP EP21842240.0A patent/EP4185566B1/en active Active
-
2022
- 2022-01-28 US US17/587,812 patent/US11548853B2/en active Active
- 2022-10-28 US US18/050,888 patent/US11827605B2/en active Active
-
2023
- 2023-10-20 US US18/491,538 patent/US12252471B2/en active Active
-
2025
- 2025-02-14 US US19/053,643 patent/US20250282730A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022015423A1 (en) | 2022-01-20 |
| US20230124135A1 (en) | 2023-04-20 |
| US11267788B2 (en) | 2022-03-08 |
| JP7867482B2 (ja) | 2026-05-29 |
| EP4185566A4 (en) | 2024-12-04 |
| EP4185566A1 (en) | 2023-05-31 |
| US20240208910A1 (en) | 2024-06-27 |
| EP4786453A2 (en) | 2026-08-05 |
| IL299756A (en) | 2023-03-01 |
| US20250282730A1 (en) | 2025-09-11 |
| US20220153703A1 (en) | 2022-05-19 |
| AU2021308209A8 (en) | 2023-04-13 |
| US11827605B2 (en) | 2023-11-28 |
| US12252471B2 (en) | 2025-03-18 |
| US20220017468A1 (en) | 2022-01-20 |
| CN116157387A (zh) | 2023-05-23 |
| US11548853B2 (en) | 2023-01-10 |
| EP4185566B1 (en) | 2026-06-24 |
| CN116157387B (zh) | 2026-06-09 |
| CA3185793A1 (en) | 2022-01-20 |
| MX2023000263A (es) | 2023-03-29 |
| JP2023533855A (ja) | 2023-08-04 |
| KR20230041021A (ko) | 2023-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12252471B2 (en) | Isoquinoline compounds and their use in treating AhR imbalance | |
| US11535606B2 (en) | Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof | |
| US20210221802A1 (en) | Novel chroman derivatives having estrogen receptor degradation activity and uses thereof | |
| WO2021238827A1 (zh) | Egfr抑制剂、其制备方法及用途 | |
| CN102408429A (zh) | 抑制醛甾酮合酶和芳香酶的稠合咪唑并衍生物 | |
| EP3532062B1 (en) | Ror-gamma modulators | |
| JP7091437B2 (ja) | オキシンドール化合物およびその医薬組成物 | |
| CN111712503A (zh) | 取代的四氢吡喃二氢噻吩并嘧啶类化合物及其作为磷酸二酯酶抑制剂的用途 | |
| US11752153B2 (en) | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | |
| EP1346993A1 (en) | Lactam compounds and medicinal use thereof | |
| EP3551633B1 (en) | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | |
| EP2875026A1 (fr) | Derive d'imidazopyridine utiles dans le traitement du diabete | |
| EP4183785A1 (en) | Novel n-heterocyclic bet bromodomain inhibitor, and preparation method therefor and medical use thereof | |
| WO2024088282A1 (zh) | 一种哒嗪酰胺类化合物、其药物组合物及其作为tyk2抑制剂的用途 | |
| US20260069585A1 (en) | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES | |
| JPS5982375A (ja) | ６−アニリノ−５，８−キノキサリンジオン類 | |
| CN117999072A (zh) | β肾上腺素能激动剂和其使用方法 | |
| WO2025237171A1 (zh) | 嘧啶并五元氮杂环酚类化合物及其应用 | |
| WO2024050431A2 (en) | Tapinarof and analogs thereof for use in treating ahr mediated diseases | |
| US9896415B2 (en) | Chalcone derivatives having an anti-allergic activity | |
| JPH08268949A (ja) | ジフェニルメチレン誘導体 | |
| CA3241167A1 (en) | Phenylethylidenehydrazine dimers and methods of using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 57 , NO 5 , PAGE(S) 786 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAMES DERMAVANT SCIENCES GMBH; AXTMAN, A., APPLICATION NO. 2021308209, UNDER INID (71) REMOVE CO-APPLICANT AXTMAN, A. |